Connect
Datopotamab Dxd; Dato-dxd, Datroway, ADC for a few metastatic cancers
Does anyone have experience with a relatively new ADC called: datopotamab deruxtecan? Dato-dxd for short, brand name is Datroway. It is FDA approved for NSCLC.
Does it seem to help? Has is stopped cancer growth at least for a time? What side effects do you experience? How bad are the side effects? Any other info?
I have metastatic breast cancer and Dato-dxd is only recently FDA approved for use in some metastatic breast cancers. Dato-dxd has been approved for metastatic NSCLC longer. I am trying to decide if taking Dato-dxd will be worth the bad side effects it seems to have per clinical trials and med journal articles.
Thank you in advance for any info you can share!
Like
Helpful
HugInterested in more discussions like this? Go to the Lung Cancer Support Group.
Connect
Hi @olivia7850, I'm not an expert, but I believe Dato-dxd is fairly newly FDA approved for lung cancer also. It's approved for EGFR based lung cancers, so only a slice of the overall lung cancer population (10-15%). Hopefully continuing research will show effectiveness for additional types too.
If one of our lung cancer members have had experience with Datroway/Data-dxd I hope they respond too. 🙂
Wishing you the best of luck with your search for treatment. I have had an early-stage breast cancer (1B), but also have a metastatic lung cancer. So, I understand the continual search for effective treatments and the hope that treatment approvals stay ahead of our needs and recurrences.
-
Like -
Helpful -
Hug
1 Reaction@lls8000
Hello Lisa:
The FDA has announced that the approval for Dato-Dxd use for in metastatic triple negative breast cancer or unresectable (cannot be surgically removed) triple negative breast cancer will be effective on May 2, 2026. That's great news and only a few weeks away.
Dato-Dxd is already approved for certain other breast cancers and for non small cell lung cancer (NSCLC).
This is fabulous news for mTNBC folks who have limited chemo/ADC options since we lack any hormone receptors. It's great to have another excellent ADC beyond sacituzumab govitecan.
@olivia7850, That is great news!, especially for a cancer with so few treatment options. Terrific!! 🙂